421 S. Lynnhaven Road
Dalos develops and sells unique topical plant-derived products for the relief of bacterial (including MRSA) and viral skin infections, as well as products for general skin care. These represent large and profitable markets with significant unmet needs. Our technology won the award at BIO 2006 as “the most innovative and commercializable technology.” All Dalos’ products have solid laboratory and clinical evidence for their activity.
Dalos focuses on sales through physicians and pharmacies, as well as direct to consumer sales via internet commerce sites. Discussions are ongoing with distributors for US and international markets. In Year Two our sales increased by 75% over Year One. We have commercialized two lead products, MersaDerm and PoxiDerm, and are preparing to launch six more. The products have been well-received by physicians and patients.
Dalos has a strong scientific advisory board, and our CEO has over 25 years of dermatology and infectious disease product development experience. We are actively seeking partnerships and distributors as well as licensing opportunities for individual indications in exchange for upfront payments and royalties. Merger or acquisition are options for the future. We are seeking up to 2 M to fund increased marketing efforts, manufacturing, and intellectual property expansion.